All Work

Chris Lange

Is Nymox a Fluke or Is It Back?

Nymox Pharmaceutical shares rallied over 100% in the past week. Was that a fluke, or is Nymox really back in business?

Chris Lange · 12 years ago

How Smartphone Dependency Is on the Rise

Who would have thought that smartphones with their multiple applications would become such a large part of daily life, or even go as far as to induce dependence?

Chris Lange · 12 years ago

Micron Earnings Trumps Value Status

Micron Technology reported better-than- expected fiscal second-quarter results Wednesday after the markets closed.

Chris Lange · 12 years ago

Is the Sears Land Plan Dead on Arrival?

Wikimedia Commons (Mike Kalasnik)Sears Holdings Corp. (NASDAQ: SHLD) has been a long-term disappointment that has always been full of potential value. The company’s inability to unlock that value has been a massive disappointment, almost…

Chris Lange · 12 years ago

Does the Mylan Secondary Make Its Stock Cheap?

Mylan has announced that it will have a 35 million share secondary offering. At Tuesday's closing price of $59.35, the offering would be valued at $2.08 billion.

Chris Lange · 12 years ago

Biotechs Raising New Capital in Droves

With the biotech industry so hot, it seems like many of the smaller players are trying to bolster their balance sheets to get enough capital for their future product pipeline plans.

Chris Lange · 12 years ago